Moore, Penelope L.Decker, Julie M.Bibollet-Ruche, F.Li, Hui.Leseka, N.Gray, Elin Solomonovna.Choge, Isaac Ang'Ang'A.Abdool Karim, Salim Safurdeen.Treurnicht, Florette K.Mlisana, Koleka Patience.Shaw, George M.Williamson, Carolyn.Morris, Lynn.2012-12-132012-12-132007-03-222007-03-22Gray, E.S. et al. 2007. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. Journal of Virology 81 (12), pp. 6187-6196.0022-538Xhttp://dx.doi.org/10.1128/jvi.00239-09http://hdl.handle.net/10413/8239The study of the evolution and specificities of neutralizing antibodies during the course of human immunodeficiency virus type 1 (HIV-1) infection may be important in the discovery of possible targets for vaccine design. In this study, we assessed the autologous and heterologous neutralization responses of 14 HIV-1 subtype C-infected individuals, using envelope clones obtained within the first 2 months postinfection. Our data show that potent but relatively strain-specific neutralizing antibodies develop within 3 to 12 months of HIV-1 infection. The magnitude of this response was associated with shorter V1-to-V5 envelope lengths and fewer glycosylation sites, particularly in the V1-V2 region. Anti-MPER antibodies were detected in 4 of 14 individuals within a year of infection, while antibodies to CD4-induced (CD4i) epitopes developed to high titers in 12 participants, in most cases before the development of autologous neutralizing antibodies. However, neither anti-MPER nor anti-CD4i antibody specificity conferred neutralization breadth. These data provide insights into the kinetics, potency, breadth, and epitope specificity of neutralizing antibody responses in acute HIV-1 subtype C infection.enAntibody formation--Immunology.Antibodies--Analysis.AIDS vaccines--Research.AIDS-related opportunistic infections.AIDS.HIV.Acute human immunodeficiency.Peer reviewed journal article